# EDGAR Filing Document

**Accession Number:** 0001738021
**File Stem:** 0000950170-25-109869
**Filing Date:** 2025-8
**Character Count:** 13856
**Document Hash:** 355e63f495951082fcbe6e76215b9a45
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-109869.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0000950170-25-109869

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Compass Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001738021
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90878
- **FILM NUMBER:** 251229220

**BUSINESS ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135
- **BUSINESS PHONE:** 617-500-8099

**MAIL ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Olivia Ventures, Inc.
- **DATE OF NAME CHANGE:** 20180419
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Commander Aggregator, LP
- **CENTRAL INDEX KEY:** 0001953093

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 2884 SAND HILL ROAD
- **STREET 2:** SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 212-909-3022

**MAIL ADDRESS:**
- **STREET 1:** 2884 SAND HILL ROAD
- **STREET 2:** SUITE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Compass Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**20454B104**

*(CUSIP Number)*

**Commander Aggregator, LP**<br>c/o The Corporation Trust Company<br>Corporation Trust Cntr, 1209 Orange St.<br>Wilmington, New Castle DE 19801<br>(302) 658-7581

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/14/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **20454B104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Commander Aggregator, LP** | Name of reporting person<br>**Commander Aggregator, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7788150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7788150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage of ownership is based upon 171,572,498 shares of common stock, par value $0.0001 per share ("Common Stock"), issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) ("Prospectus") with the Securities and Exchange Commission ("SEC") on August 13, 2025.

| **CUSIP No.** | **20454B104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Enavate Sciences, LP** | Name of reporting person<br>**Enavate Sciences, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7788150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7788150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

| **CUSIP No.** | **20454B104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Enavate Sciences GP, LLC** | Name of reporting person<br>**Enavate Sciences GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7788150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7788150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

| **CUSIP No.** | **20454B104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Enavate Sciences Holdings, LLC** | Name of reporting person<br>**Enavate Sciences Holdings, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**7788150.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**7788150.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | Aggregate amount beneficially owned by each reporting person<br>**7788150.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.5%** | Percent of class represented by amount in Row (11)<br>**4.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Percentage of ownership is based upon 171,572,498 shares of Common Stock issued and outstanding, effective as of August 14, 2025, as set forth in the Issuer's Prospectus filed with the SEC on August 13, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Compass Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
80 Guest St., Suite 601, Boston, MA, 02135

This Amendment No. 1 ("Amendment No. 1") to Schedule 13D amends and supplements the initial Schedule 13D filed on November 14, 2022 (as so amended, the "Schedule 13D"). Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D as amended from time to time.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of this Statement is hereby amended and restated in its entirety as follows:

The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.

**(b)**
Item 5(b) of this Statement is hereby amended and restated in its entirety as follows:

The information set forth in rows (11) and (13) of the cover pages of this Statement is incorporated by reference into this Item 5.

**(c)**
None of the Reporting Entities has effected any transactions in the Common Stock in the past 60 days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Commander Aggregator, LP

**Signature:** /s/ James P. Boylan

**Name/Title:** James P. Boylan / Chief Executive Officer

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Enavate Sciences, LP

**Signature:** /s/ James P. Boylan

**Name/Title:** James P. Boylan / Chief Executive Officer

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Enavate Sciences GP, LLC

**Signature:** /s/ James P. Boylan

**Name/Title:** James P. Boylan / Chief Executive Officer

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Enavate Sciences Holdings, LLC

**Signature:** /s/ James P. Boylan

**Name/Title:** James P. Boylan / Chief Executive Officer

**Date:** 08/18/2025